PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515451
PUBLISHER: AnalystView Market Insights | PRODUCT CODE: 1515451
Rare Biomarkers Specimen Collection and Stabilization Market size was valued at USD 36,908.32 Million in 2023, expanding at a CAGR of 13.90% from 2024 to 2032.
Rare biomarkers specimen collection and stabilization refers to the process of obtaining biological samples such as blood, urine, tissue, etc. that contain rare or low-abundance biomolecules, which are substances indicative of biological processes or conditions. These biomarkers may be present in very small quantities in the body and can provide critical information about disease states, treatment responses, or physiological changes.
Rare Biomarkers Specimen Collection and Stabilization Market- Market Dynamics
Rising number of drug development & clinical trials and biomedical research are expected to propel market demand
Biomarkers are increasingly used as endpoints in clinical trials to assess drug efficacy and safety. Proper collection and stabilization of rare biomarkers are critical to ensuring the reliability and reproducibility of trial results. Moreover, innovations in sample handling technologies, such as improved stabilizing agents, storage conditions, and transport systems, enhance the reliability and efficiency of rare biomarker collection and stabilization processes. Thus, high demand from clinical trials & advancement in technology is expected to foster market growth.
Technological developments in biotechnology and molecular biology have increased our capacity to find and examine uncommon biomarkers. This emphasizes the necessity for trustworthy techniques for stabilizing and collecting specimens while maintaining the integrity of the biomarker which is contributing to market growth. Treatments are becoming more individualized considering patient genetic, environmental, and biomarker profiles known as personalized medicine. To pinpoint patient-specific traits that affect therapy efficacy and outcomes, rare biomarkers are essential. There is a growing emphasis on cost-effective healthcare solutions. Biomarker-based diagnostics can potentially reduce overall healthcare costs by enabling early disease detection and targeted therapies.
Rare Biomarkers Specimen Collection and Stabilization Market- Key Insights
As per the analysis shared by our research analyst, the global market is estimated to grow annually at a CAGR of around 13.90% over the forecast period (2024-2032)
Based on Biomarker segmentation, circulating cell-free DNA (ccfDNA) segment was predicted to show maximum market share in the year 2023, owing to its high demand in cancer treatment.
Based on Application segmentation, diagnostics segment was the leading application in 2023, due to increased need for chronic disorder care.
Based on End User segmentation, research laboratories segment was the leading End User in 2023, owing to high focus on drug development & novel research.
On the basis of region, North America was the leading revenue generator in 2023, owing to government support & FDA approvals.
The Global Rare Biomarkers Specimen Collection and Stabilization Market is segmented on the basis of Biomarker, Application, End User, and Region.
The market is divided into three categories based on Biomarker: circular cell free DNA, circulating tumor cells, and exosomes. The circular cell free DNA segment dominates the market. High prevalence of blood cancer is primarily boosting segment growth.
The market is divided into five categories based on Application: diagnostics, transcriptomics, pharmacogenomics, cardiovascular diseases, and others. The diagnostics segment dominates the market. The increasing need for treatment of non-invasive cancer and clinical use is accelerating market growth.
The market is divided into three categories based on End User: research laboratories, hospital & clinics, and others. The research laboratories segment dominates the market and is expected to maintain its high dominance during the forecast period. The increasing encouragement from government & FDA approvals in DNA & RNA drug development are boosting market growth.
Rare Biomarkers Specimen Collection and Stabilization Market- Geographical Insights
Geographically, this market is widespread in the regions of North America, Latin America, Europe, Asia Pacific, and the Middle East and Africa. North America, mainly the United States, is a mature market for advanced biomedical research and diagnostics. Several factors like the presence of leading academic institutions, research centers, and biotechnology companies drive demand for advanced specimen collection and stabilization technologies. In addition, significant healthcare spending and insurance coverage facilitate adoption of advanced diagnostic technologies.
The competitive landscape of the rare biomarkers specimen collection and stabilization market is shaped by technological advancements, dominated by major players. some of the leading companies in the market such as Thermo Fisher Scientific, QIAGEN, BD Biosciences, Merck KGaA, etc., dominate market share due to their extensive product offerings and global presence. These companies are investing in research and development to innovate new specimen collection devices and stabilization methods that improve biomarker preservation and reliability.
In March 2023, nRichDX partnered with OraSure Technologies, Inc., to market their products for scientists working on liquid biopsy applications.
In May 2023, LabCorp launched LabCorp Plasma Focus, a liquid biopsy test which enables tailored therapy selection for people with advanced or metastatic solid cancers.